Inhibrx Biosciences, Inc.

NASDAQ:INBX

Biotechnology

Healthcare
$69.06 -2.74%

-$2.58 today

Market cap
$1.02B
Beta
3.32
P/E (TTM)
-11.0
EPS (TTM)
-$8.35
52W Low $13.97High $155.29

Volume 0.29M

Average 0.43M

INBX Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Inhibrx Biosciences, Inc.NASDAQ: INBX

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$30.93M, compared with -$42.9M a year earlier. Trailing-twelve-month operating income was -$123.05M.

Context

  • Operating income amounted to 10386.5% of revenue in FY2025, down 155337.5 pp from a year earlier.
  • Operating income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 2 analysts of -$125.43M (+7.1%) for the fiscal year ending Dec 2026, a slowdown from the +59.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$30.93M-0.0% QoQ
Last fiscal yearDec 2025
-$135.03M+59.3% YoY
LTMMar 2026
-$123.05M+59.1% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+27.9%——
1 year+59.3%+7.1%-52.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(135.03M) USD
Year-over-year change
+59.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How INBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +59.1% is the highest of 7, against a peer median of -34.4%.
  • Operating income amounts to 9465.5% of revenue for INBX, versus a peer median of 737.0%.
INBX Competitors
Operating Income for INBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TECXTectonic Therapeutic, Inc.LTM Mar 2026-$93.04M USD-46.9%——
INBXInhibrx Biosciences, Inc.LTM Mar 2026-$123.05M USD+59.1%—9465.5%
ABSIAbsci CorporationLTM Mar 2026-$128.54M USD-13.6%—7000.8%
JANXJanux Therapeutics, Inc.LTM Mar 2026-$156.98M USD-38.2%—726.3%
IMTXImmatics N.V.LTM Mar 2026-€212.71M EUR-251.5%—570.3%
GENBGenerate Biomedicines, Inc.FY2025-$235.07M USD-19.4%—737.0%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$334.5M USD-30.5%—298657.1%
Peer median (excluding INBX) —-34.4%—737.0%

Competitors are the stored peer set for INBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.13M2.19M1.8M200K1.3M
Cost of Revenue2.69M110.19M1.19M2.29M2.48M
Gross Profit4.44M(107.99M)609K(2.09M)(1.18M)
Gross Margin62.3%-4926.7%33.8%-1042.5%-91.0%
Research & Development71.44M110.19M190.65M203.74M113.03M
Selling, General & Admin12.36M21.12M29.38M127.91M23.3M
Operating Expenses12.34M21.12M219.83M329.36M133.84M
Depreciation & Amortization1.2M1.23M1.19M2.29M2.48M
EBITDA(75.37M)(125.82M)(206.69M)1.7B(132.54M)
EBITDA Margin-1057.8%-5739.8%-11482.9%851675.0%-10195.5%
Operating Income(76.56M)(129.12M)(219.22M)(331.45M)(135.03M)
Operating Margin-1074.6%-5890.4%-12178.9%-165724.0%-10386.5%
Interest Income5.22M16.11M11.92M10.94M7.55M
Interest Expense5.22M16.11M31.84M13.49M12.2M
Other Income / Expenses(5.2M)(16.11M)(20.5M)2.02B(5.03M)
Income Before Tax(81.77M)(145.22M)(239.72M)1.69B(140.05M)
Pre-Tax Margin-1147.6%-6625.1%-13318.0%843787.0%-10773.3%
Income Tax Expense2K3K3K2K2K
Net Income(81.77M)(145.23M)(241.36M)1.69B(140.06M)
Net Margin-1147.6%-6625.3%-13408.9%843786.0%-10773.5%
EPS (Basic)(2.15)(3.62)(5.12)116.58(9.04)
EPS (Diluted)(2.15)(3.62)(5.12)116.58(9.04)
Weighted Avg Shares38.01M40.11M47.13M14.48M15.49M
Weighted Avg Shares (Diluted)38.01M40.11M47.13M14.48M15.49M

Inhibrx Biosciences, Inc.

NASDAQ:INBX

Intrinsic Alpha fair value

Locked

Current Price

$69.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.